Department of Vascular Surgery, Quzhou People's Hospital, Quzhou City, 324000, Zhejiang Province, China.
Department of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, 150006, China.
J Nanosci Nanotechnol. 2021 Feb 1;21(2):1236-1243. doi: 10.1166/jnn.2021.18689.
Hemangiomas, also called infantile hemangiomas (IH), are the most common congenital benign vascular tumors in infants and young children. At present, there are many treatment methods for proliferative hemangiomas, which have different effects and lack predictability. Propranolol has gradually replaced glucocorticoids as the first-line treatment for infants and young children with hemangiomas. However, premature discontinuation is prone to relapse, and the efficacy and safety of medication need to be further studied and determined. The exact pathogenesis of hemangiomas is still unclear. Therefore, in this study, poly(lactic-co-glycolic acid) (PLGA) nanoparticles were used as drug delivery carriers, propranolol was encapsulated, and PLGA-propranolol (PLGA-PP) nanodelivery preparations were prepared and targeted. Anisotropy and pharmacokinetics were preliminary studied. At the same time, after the treatment of HemECs cells with PLGA-PP in gradient concentration , CCK-8 method was used to detect the cell proliferation, and Anyixin-V/PI double staining method was used to detect the apoptosis rate of cells. The effect of PLGA-PP nano-delivery vector on hemangioma was studied by western blot method to detect the expression level of Id-1 protein in HemECs. The results showed that after PLGA-PP treated HemECs for 24 h, PLGA-PP significantly inhibited HeECs proliferation and promoted their apoptosis, and the intracellular Id-1 protein expression was also reduced. Therefore, this study believes that the mechanism of PLGA-PP nano-targeted delivery preparations in the treatment of hemangiomas is achieved by down-regulating the Id-1 gene, thereby inhibiting the colonization of HemECs and promoting its apoptosis effect.
血管瘤，又称婴儿血管瘤（IH），是婴儿和幼儿中最常见的先天性良性血管肿瘤。目前，增殖性血管瘤有多种治疗方法，效果不同，缺乏可预测性。普萘洛尔已逐渐取代糖皮质激素成为婴幼儿血管瘤的一线治疗药物。然而，过早停药容易复发，药物的疗效和安全性需要进一步研究和确定。血管瘤的确切发病机制尚不清楚。因此，在本研究中，聚（乳酸-共-乙醇酸）（PLGA）纳米粒子被用作药物载体，包裹普萘洛尔，并制备和靶向 PLGA-普萘洛尔（PLGA-PP）纳米递药制剂，初步研究了各向异性和药代动力学。同时，在梯度浓度的 PLGA-PP 处理 HemECs 细胞后，采用 CCK-8 法检测细胞增殖，采用 Anisixin-V/PI 双重染色法检测细胞凋亡率。采用 Western blot 法检测 HemECs 中 Id-1 蛋白的表达水平，研究 PLGA-PP 纳米递药载体对血管瘤的作用。结果表明，PLGA-PP 处理 HemECs 24 h 后，PLGA-PP 显著抑制 HeECs 增殖，促进其凋亡，细胞内 Id-1 蛋白表达也降低。因此，本研究认为 PLGA-PP 纳米靶向递药制剂治疗血管瘤的机制是通过下调 Id-1 基因，抑制 HemECs 的定植和促进其凋亡作用来实现的。
